Home > Boards > US OTC > Medical - Equipment >

Cerebain Biotech Corp. (CBBT)

Add CBBT Price Alert      Hide Sticky   Hide Intro
Moderator: Golden_Cross, stox777
Search This Board: 
Last Post: 5/23/2019 12:27:20 PM - Followers: 110 - Board type: Free - Posts Today: 2


Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.

Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.

About the Omentum

Generally described as a protective layer in the abdomen, the omentum covers the intestines, hangs on to the stomach and can be lifted like a flap. While the omentum is not a well-recognized body part, it can play important healing and protective roles for its host.

Protection: The omentum has abundant blood and lymphatic vessels, and can move flexibly throughout the abdomen to protect organs from threat and injury.

Healing: Additionally, it contains the largest supply of stem cells in the adult body. Because of its abundant blood supply, surgeons have long used the omentum to patch internal injuries sustained to other parts of the body.

Cerebain’s Technology

Patent-pending technology has allowed for the development of a medical device that can
be implanted using a minimally invasive procedure.

Once implanted via what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

Cerebain has a manufacturing agreement with Sonos Medical, a trusted and reliable medical device supplier.

Clinical Trials

The Company is now in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.

Potential for a Personalized Approach to
Treatment for Alzheimer’s Disease Patients

As clinical trials are conducted and variables are put into play (e.g., frequency of stimulation, duration, location, etc.,) we may find that individuals respond differently and require individualized treatment plans. Cerebain’s device can potentially provide this, making our ability to positively impact the lives of as many Alzheimer’s Disease patients as possible.

In 2010 Cerebain Biotech licensed patent-pending technology for an implantable device that stimulates the omentum, and can be adjusted non-invasively to account for a range of factors, including frequency, strength of stimulation and location.


Company Overview

Existing therapeutics have been unable to halt disease progression or extend life in a meaningful way

Cerebain’s novel device approach is supported by research and patient outcomes

Clinical evidence supports the Company’s working approach, that omentum stimulation improves cognitive function in patients with dementia, including Alzheimer’s Disease

Minimally invasive, one-time device implantation will overcome challenges associated with previous omentum stimulation procedures that are highly invasive

Patent-pending technology with broad applicability

Recent scientific breakthroughs regarding the potential identification of gene-specific protein increases prior to on-set of symptoms, could compliment our work

Early diagnosis is key to helping patients maintain quality of life http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet

Experienced management and advisory teams with the expertise to move the clinical program forward efficiently and effectively


Corporate Leadership


Eric Clemons, President and CEO
e-mail:  clemons@cerebain.com

Mr. Clemons has a long history building and growing companies across multiple industries. Prior to assuming leadership of Cerebain, he served as President and Chief Operating Officer for GTC Telecom Corp, a publicly traded Nevada Corporation that operated out of Costa Mesa, CA. During his tenure, Mr. Clemons was instrumental in growing the company’s annual revenues from $500,000 per year to over $17 million per year.

It was Cerebain technology, which offers a completely new way of approaching the development of an effective Alzheimer’s disease treatment that captured Mr. Clemons’ imagination, triggering his move into the life sciences arena.

“While there have been some very recent key learnings in the Alzheimer’s treatment space, the fact is that the disease remains the only top ten killer in the United States with no effective treatments currently available and no way to halt or slow progression,” Clemons said. “We are hopeful that our device, which will focus on the impact of omental stimulation and cognitive function in Alzheimer’s Disease patients, can change that.”

Wesley Tate – Chief Financial Officer
e-mail:  wtate@cerebain.com

Prior to joining Cerebain Biotech, Mr. Tate was the owner of Strategic Business Associates, a Tennessee-based consultancy offering business management and growth services to start-up and early-stage companies.

Over the course of his career Mr. Tate has held key managerial positions at both healthcare and telecoms companies. This includes Chief Financial Officer for HST Global, Inc., a development-stage biotechnology company located in Virginia; and Executive Vice President and Chief Operating Officer for InnerLight Inc., a life science company located in Utah.

Mr. Tate received his Bachelor of Science degree from the University of Tennessee, Knoxville, with majors in Finance and Psychology, and earned his Masters of Business Administration from the University of Tennessee, Knoxville, with concentrations in Finance and Management.

He is proud to have served his country as a member of the United States Army.


Held at DTC
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#3014   Eric and Wesley got bills to pay.... Google Cowman45 05/23/19 12:27:20 PM
#3013   Management killing this stock with relentless dilution. One OINGO BOINGO 05/23/19 11:46:51 AM
#3012   Another ugly one. If anything at least they're OINGO BOINGO 05/20/19 07:13:54 PM
#3011   10q out StockProfit 05/20/19 02:33:45 PM
#3010   CBBT Daily Chart Golden_Cross 05/17/19 06:49:54 PM
#3009   CBBT - 2.3 million buy at .0023. findit 05/15/19 02:51:44 PM
#3008   Got my worthless 14c in the mail today. OINGO BOINGO 05/14/19 05:26:26 PM
#3007   I kinda agree abazaba375 05/11/19 10:23:38 PM
#3006   God I hope so very deep in red. OINGO BOINGO 05/11/19 06:52:30 PM
#3005   I think something big will happen this week JLS19 05/11/19 04:51:56 PM
#3004   CBBT Daily Chart: Golden_Cross 05/10/19 10:29:03 AM
#3003   Bounce time Golden_Cross 05/10/19 10:26:30 AM
#3002   I did too bad you missed it 12ka 05/10/19 09:39:52 AM
#3001   CBBT back on watch sharky 05/10/19 09:33:57 AM
#3000   Not a chartist by no means but need OINGO BOINGO 05/10/19 09:32:19 AM
#2999   The man does the charting.. why don't you justanotherfigment 05/10/19 09:22:51 AM
#2998   Have a Great Day... georgie18 05/10/19 09:18:16 AM
#2997   everywhere really,you realize that I posted only on 12ka 05/10/19 09:16:21 AM
#2996   Raised authorize pay notes but not a word OINGO BOINGO 05/10/19 09:04:08 AM
#2995   Your not following me around but yet you georgie18 05/10/19 08:47:11 AM
#2994   I am not following you man,but everywhere you 12ka 05/10/19 08:38:44 AM
#2993   You appear to be quite emotional about my georgie18 05/10/19 04:53:27 AM
#2992   to pay their notes they owe,millions in notes 12ka 05/10/19 04:46:39 AM
#2991   F your PSAR flip they slow bleeding the 12ka 05/10/19 04:38:32 AM
#2990   He jus joe117 05/09/19 05:53:41 PM
#2989   maxm gone Rainer 05/09/19 12:12:53 PM
#2988   5s will come perhaps one day OINGO BOINGO 05/09/19 11:23:22 AM
#2987   .005s today RetroSpect 05/08/19 08:13:24 AM
#2986   Hard to say. If you read the 14c OINGO BOINGO 05/07/19 01:36:24 PM
#2985   Well the selling has stopped (at least temporarily) CollegeGrad22 05/07/19 01:10:13 PM
#2984   Based on the news and the increase in Maso11 05/07/19 12:44:19 PM
#2983   When they do add the new AS, do findit 05/07/19 12:38:33 PM
#2982   Sorry my bad was talking the new authorized OINGO BOINGO 05/07/19 12:13:59 PM
#2981   From the looks of the chart, it’s already CollegeGrad22 05/07/19 11:59:07 AM
#2980   It's gonna be raining shares hallelujah OINGO BOINGO 05/07/19 11:55:33 AM
#2979   .004s coming again RetroSpect 05/07/19 11:50:52 AM
#2978   You and me both. OINGO BOINGO 05/07/19 11:44:21 AM
#2977   CBBT...0031...Psar flipped to a Bullish Buy Position...will see georgie18 05/07/19 11:42:45 AM
#2976   Lol Polly want cbbt shares Polly want cbbt OINGO BOINGO 05/07/19 11:42:06 AM
#2975   You don’t need to be a psychic to ryoon21 05/07/19 11:26:22 AM
#2974   Wrong. New AS shares have not even findit 05/07/19 11:17:54 AM
#2973   Correct S3lfMade 05/07/19 11:07:53 AM
#2972   The big pump before the massive 1.2B dump. joe117 05/07/19 11:04:08 AM
#2971   Yeah big bangs on ASK ! Go CBBT - TruckingAngler 05/07/19 10:55:24 AM
#2970   Correction, 1 billion common shares. ryoon21 05/07/19 10:40:15 AM
#2969   I really don’t know. It’s acting opposite of ryoon21 05/07/19 10:37:25 AM
#2968   What’s the deal here ? slickinvest 05/07/19 10:33:59 AM
#2967   Holy moly... ryoon21 05/07/19 10:29:00 AM
#2966   I’ve got a long way to go... ryoon21 05/07/19 10:22:52 AM
#2965   Nice big buys now. Thank goodness we’re crawling TruckingAngler 05/07/19 10:22:14 AM